Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.73 Average Price Target from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus rating of “Buy” by the twelve research firms that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $57.73.

MIRM has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Citigroup boosted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners increased their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th.

Insider Activity

In other news, SVP Jolanda Howe sold 2,500 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the transaction, the senior vice president now directly owns 2,426 shares in the company, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the period. Amalgamated Bank grew its position in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after buying an additional 513 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock valued at $315,000 after buying an additional 883 shares during the period. Quest Partners LLC raised its position in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its position in Mirum Pharmaceuticals by 17.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock valued at $480,000 after purchasing an additional 2,050 shares during the period.

Mirum Pharmaceuticals Trading Up 0.6 %

MIRM opened at $42.65 on Friday. The firm has a market cap of $2.05 billion, a PE ratio of -21.11 and a beta of 1.20. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $48.89. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm’s fifty day moving average is $42.04 and its two-hundred day moving average is $39.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s quarterly revenue was up 89.4% on a year-over-year basis. During the same period last year, the business posted ($0.57) earnings per share. Equities research analysts anticipate that Mirum Pharmaceuticals will post -1.48 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.